fusafungin and Pharyngitis

Topics: Administration, Inhalation; Adult; Aged; Bacterial Infections; Depsipeptides; Female; Fusarium; Humans; Male; Middle Aged; Mouth Mucosa; Pharyngitis; Severity of Illness Index

Eighty-one patients suffering from follicular pharyngitis were treated for 7 days in a double-blind, multicentre controlled study of fusafungine versus placebo. Evaluations were performed at inclusion, after 7 days of treatment, and 3 weeks after the end of the treatment. The effects of the pharyngitis on day-to-day life, changes in symptoms, morphological changes of lesions, and general changes observed by the investigator and expressed by the patient were the parameters evaluated at each visit. Results confirmed the efficacy of fusafungine in the treatment of local and symptomatic manifestations of follicular pharyngitis. Effects of follicular pharyngitis on day-to-day life decreased after 7 days of treatment and the differences between the treatment group and the placebo group was close to significance in favour of fusafungine. For the majority of symptoms, the percentage of patients who did not display the symptoms at D7 was greater in the fusafungine group. Postnasal drip decreased significantly in the fusafungine group. The investigators' and patients' judgement was also in favour of the fusafungine treatment. These improvements were confirmed at least 3 weeks after the end of the treatment.

Topics: Administration, Inhalation; Administration, Intranasal; Adult; Aerosols; Aged; Aged, 80 and over; Anti-Bacterial Agents; Chi-Square Distribution; Depsipeptides; Double-Blind Method; Female; Fusarium; Humans; Male; Middle Aged; Pharyngitis; Statistics, Nonparametric; Treatment Outcome

An open clinical trial of Locabiotal, in which the antibiotic, fusafungine, is presented in a micronized aerosol was performed in general practice. One hundred and ten patients suffering from upper respiratory infections without associated hyperpyrexia or toxic symptoms were treated for 7 days. There was a marked improvement in the symptoms rated during the first 48 hours. After the full course of treatment 37 patients regarded its effect as excellent and 48 as good.

Topics: Adolescent; Adult; Aerosols; Aged; Anti-Bacterial Agents; Child; Child, Preschool; Common Cold; Depsipeptides; Female; Humans; Laryngitis; Male; Middle Aged; Pharyngitis; Respiratory Tract Infections; Rhinitis